Treatments

*September 2022* The clinical significance of gene fusions detected by DNA-based next generation sequencing remains unclear as resistance mechanisms to EGFR tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer. By studying EGFR inhibitor-resistant patients treated with a combination of an EGFR inhibitor and a drug targeting the putative…

*October 2022* What happens when your cancer becomes resistant to your course of treatment and progresses? Dr. David Gandara, professor emeritus and co-director of UC Davis Comprehensive Cancer Center’s Center for Experimental Therapeutics, discussed a number of options. The good news is that it turns out there’s a lot that…

*September 2022*  From Dr. Julien Mazieres' presentation at ESMO 2022

*September 2022* Topline data presented at ESMO 2022 showed DZD9008 met its primary end point of objective response rate and had a benign safety profile in non–small cell lung cancer with EGFR exon 20 insertion mutations. DZD9008 (sunvozertinib) in patients with platinum-pretreated non–small cell lung cancer (NSCLC) with EGFR exon…

*September 2022* Trastuzumab deruxtecan (Enhertu) demonstrated clinically meaningful benefit and a favorable safety profile at the lower of 2 dose levels in patients with HER2-mutated non–small cell lung cancer (NSCLC), according to interim results of the DESTINY-Lung02 trial (NCT04644237) presented at the 2022 European Society for Medical Oncology (ESMO) Congress.1…

*September 2022* Fine particulate matter from the combustion of fossil fuels seemed to trigger non-small cell lung cancer (NSCLC) in never smokers through a process of "tumor promotion," according to a study on the etiology of EGFR-mutated disease. The link was first suggested decades ago and long overlooked, but now…

*June 2022* Highlights: Alternation of osimertinib and afatinib was evaluated for patients with metastatic treatment-naïve EGFR-mutated NSCLC in this phase 2 trial. Although the 12-month PFS probability was 70.2%, which did not meet the primary end point, the median PFS was 21.3 months suggesting the promising efficacy of this alternative…

*September 2022* Lung cancer specialist Lecia V Sequist, MD, MPH discusses the current and future management of EGFR NSCLC with host Dr. Neal Love. This informative presentation is available in the following formats: video, audio, and powerpoint slides.  Listen to the audio/read transcription here.  Watch the video/download slides here. Please…

*August 2022* Alexander I. Spira, MD, PhD, FACP, research institute director, Thoracic and Phase 1 Trial Program, Virginia Cancer Specialists Research Institute, Virginia Cancer Specialists, clinical assistant professor, Johns Hopkins University, discusses additional studies investigating the use of lazertinib (Leclaza) and amivantamab-vmjw (Rybrevant) in EGFR-mutated non–small cell lung cancer (NSCLC).…

*August 2022* From WCLC Abstract presented by Dr. Jie Huang Introduction: Small cell lung cancer (SCLC) transformation remains one of the unsettled resistant mechanisms for lung adenocarcinoma (LUAD), of which co-occurring TP53 and RB1 mutations defined a subgroup of patients with increased risk of SCLC transformation. Our study aimed to…